1Newcomer JW. Second- generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 2005;19(Suppl 1) : 1-93.
2O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol, 2008;22(2 Suppl) :70-75.
3Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry, 2007 ; 190:129-134.
4Kunimatsu T, Kimura J, Funabashi H, et al. The antipsychoties haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regul Toxicol Pharmacol.2010;58(3) :360-368.
5Saekett G, Unis A, Crouthamel B. Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques. J Child Adolesc Psychopharmacol, 2010;20(6) : 489-493.
6Hui SL, Slemenda CW, Johnston CC, et al. Age and bone mass as predictors of fracture in a prospective study. Journal of Clinical Investigation, 1988 ; 81 (6) : 1804-1809.
7Koppelman MCS, Kurtz DW, Morrish KA, et al. Vertebral bone mineral density content in hyperprolactinemic women. J Clin Endocrinol Metab. 1984; 59 : 1050-1053.
8Greenspan SL, Neer RM, Ridgway EC, et al. Osteoporosis in men with hyperprolactinemic hypogonadism. Annals of Internal Medicine, 1986; 104: 777-782.
9Baastrup PC, Christiansen C, Transbol I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology, 1980;6 (1) : 56-59.
10Meaney AM, Smith S, Howes OD, et al. Effects of long term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry, 2004; 184: 503-508.
